产品封面图
文献支持

Hypoxyprobe-Red549 Kit (100 mg

pimonidazole HCl plus 1 unit of 4.3.11.3 Rat Dylight™549-MAb)
收藏
  • $398
  • Hypoxyprobe
  • HP7-100Kit
  • 美国
  • 2026年05月06日
    avatar
  • 企业认证

    点击 QQ 联系

    • 详细信息
    • 询价记录
    • 文献和实验
    • 技术资料
    • 库存

      5

    • 英文名

      Hypoxyprobe-Red549 Kit (100 mg pimonidazole HCl plus 1 unit of 4.3.11.3 Rat Dylight™549-MAb)

    • CAS号

      详询

    • 保质期

      详询

    • 供应商

      北京孚博生物科技有限公司

    • 保存条件

      未知

    • 规格

      100mg

    Hypoxyprobe-Red549 Kit (100 mg pimonidazole HCl plus 1 unit of 4.3.11.3 Rat Dylight™549-MAb)
    Item# HP7-100Kit
    $398.00

    风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。

    • 作者
    • 内容
    • 询问日期
    图标文献和实验
    该产品被引用文献

    Hypoxyprobe, Inc. is a small company dedicated to providing tools for the diagnosis and treatment of malignant and normal tissue diseases in which oxygen regulation is disturbed. The company is located at 121 Middlesex Turnpike, Burlington, Massachusetts, USA 01803 and is a spin-off of the Hypoxyprobe Division of Natural Pharmacia International, Inc. (NPI).

    Hypoxyprobe, Inc. arose from a collaboration between Dr. James Raleigh in the Department of Radiation Oncology at the University of North Carolina at Chapel Hill and NPI which at the time was located in the Research Triangle Park, North Carolina.

    The collaboration between UNC Chapel Hill and NPI at first focused on clinical studies of tumor hypoxia. NPI manufactured pimonidazole HCl on a large scale and Dr. Raleigh provided patented antibody reagents for detecting the binding of pimonidazole to hypoxic cells in human tumors.

    Preclinical studies in dogs, rats and mice generated a growing interest among the scientific community in pimonidazole HCl as a hypoxia marker in general and in 2002 NPI issued a five-year exclusive license to Chemicon International to market a limited line of Hypoxyprobe reagents for animal use. In 2006, anticipating a need for an expanded line of Hypoxyprobe reagents, NPI ended Chemicon’s license and established Hypoxyprobe, Inc. to develop an enhanced line of reagents for both animal and clinical studies.

    The Company is now focused on developing non-invasive hypoxia markers and hypoxia dependent cytotoxins based on the pimonidazole core structure.

    相关实验
    图标技术资料

    资料下载:

    1744253036100.jpg 附 (下载 1 次)

    同类产品报价

    产品名称
    产品价格
    公司名称
    报价日期
    询价
    上海北诺生物科技有限公司
    2025年06月24日询价
    ¥2625
    北京孚博生物科技有限公司
    2025年07月16日询价
    询价
    北京柏瑞图科技有限公司
    2026年02月19日询价
    ¥2502
    杭州开泰生物技术有限公司
    2025年12月18日询价
    ¥1973
    广州威佳科技有限公司
    2025年07月13日询价
    文献支持
    Hypoxyprobe-Red549 Kit (100 mg pimonidazole HCl plus 1 unit of 4.3.11.3 Rat Dylight™549-MAb)
    $398